NewAmsterdam Pharma Company N.V.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: NewAmsterdam Pharma Company N.V.
Ownership: Public
Status: Active
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Netherlands
Headquarters city: Narrden
Headquarters country: Netherlands
Fiscal year end: December
Ticker symbol: NAMS
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001936258

Board of directors

Follow this board

Adele M. Gulfo · Director
Since 2025
Der Kamp Hilde Johanna Van · Director
Since 2023
Hugo Alexander Slootweg · Director
Since 2023
James N. Topper · Director
Since 2023
Johannes Jacob Pieter Kastelein · Director · Chief Scientific Officer
Since 2023
John W. Smither · Director
Since 2023
Juliette Berangere Audet · Director
Since 2023
Louis G. Lange · Director
Since 2023
Mark C. McKenna · Director Overboarded
Since 2024
Michael H. Davidson · Director · Chief Executive Officer
Since 2023
Nicholas Downing · Director
Since 2023
William Lewis · Director
Since 2024
Wouter Joustra · Director
Since 2024

Chief executives

Michael H. Davidson · Chief Executive Officer

Since December 2023

0 CEO score

Weak · grade F

Out of 100, from shareholder return, dividends, growth and acquisitions.

Partial: only 20% of the scoring weight is on file.

Revenue growth 20%: 0

20% of the scoring weight is on file. Figures cover December 2022 – December 2025.

Director election results

Annual meeting of June 2, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

John W. Smither

98.9%

Board connections

9 of this board's directors also sit on 18 other boards.

Shared director Other board Same sector +2 more in the list below

Attovia Therapeutics Inc.
via James N. Topper and John W. Smither
AnaptysBio Inc.
via James N. Topper
BioAge Labs Inc.
via Michael H. Davidson
BridgeBio Oncology Therapeutics Inc.
via Mark C. McKenna
Enpro Inc.
via Adele M. Gulfo
Freenome Inc.
via Mark C. McKenna
Genelux Corporation
via John W. Smither
Heartflow Inc.
via Nicholas Downing
Helix Acquisition Corp. III
via Mark C. McKenna
Insmed Incorporated
via William Lewis
Phathom Pharmaceuticals Inc.
via James N. Topper
Replimune Group Inc.
via Hugo Alexander Slootweg
Silence Therapeutics Plc American Depository Share
via Michael H. Davidson
Spyre Therapeutics Inc.
via Mark C. McKenna
Tenax Therapeutics Inc.
via Michael H. Davidson
Tyra Biosciences Inc.
via Adele M. Gulfo
Vor Biopharma Inc.
via Wouter Joustra
enGene Therapeutics Inc.
via Wouter Joustra

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $226,500; 1 purchase by 1 insider
Sold, last 12 months: $61,996,069; 42 sales by 6 insiders

Date	Insider	Transaction	Shares	Price	Value
Sep 14, 2026	Michael H. Davidson Director, Officer (Chief Executive Officer)	Open-market purchase	+10,000	$22.65	$226,500
Sep 4, 2026	John W. Smither Director	Open-market sale	−1,600	$25.32	$40,512
Sep 1, 2026	Gunning Robert William Officer (Vice President, Controller)	Grant or award	+3,200	—	—
Aug 24, 2026	Johannes Jacob Pieter Kastelein Director, Officer (Chief Scientific Officer)	Option exercise	+125,000	—	—
Aug 24, 2026	Johannes Jacob Pieter Kastelein Director, Officer (Chief Scientific Officer)	Open-market sale	−125,000	$26.91	$3,363,750
Jul 20, 2026	Kooij Louise Frederika Officer (Chief Accounting Officer)	Option exercise	+25,000	$11.90	$297,500
Jul 20, 2026	Kooij Louise Frederika Officer (Chief Accounting Officer)	Option exercise	+80,000	$11.17	$893,600
Jul 20, 2026	Kooij Louise Frederika Officer (Chief Accounting Officer)	Open-market sale	−70,200	$29.96	$2,103,192
Jul 20, 2026	Kooij Louise Frederika Officer (Chief Accounting Officer)	Open-market sale	−31,885	$31.05	$990,029
Jul 20, 2026	Kooij Louise Frederika Officer (Chief Accounting Officer)	Open-market sale	−2,915	$31.71	$92,435
Jun 22, 2026	Kooij Louise Frederika Officer (Chief Accounting Officer)	Option exercise	+25,000	$10.90	$272,500
Jun 22, 2026	Kooij Louise Frederika Officer (Chief Accounting Officer)	Option exercise	+15,000	$11.90	$178,500
Jun 22, 2026	Kooij Louise Frederika Officer (Chief Accounting Officer)	Open-market sale	−39,700	$30.20	$1,198,940
Jun 22, 2026	Kooij Louise Frederika Officer (Chief Accounting Officer)	Open-market sale	−300	$30.73	$9,219
May 26, 2026	Kooij Louise Frederika Officer (Chief Accounting Officer)	Option exercise	+60,000	$10.00	$600,000

Reviews (0)

No reviews yet. Be the first to write one.